Zheng Quan Zhi Xing·2025-08-21 16:59Group 1 - The core viewpoint of the article is that China International Capital Corporation (CICC) has conducted a qualification review for the shareholders of Shanghai Mengke Pharmaceutical Co., Ltd. regarding their inquiry for share transfer to specific institutional investors [1][5] - CICC received a commission from the shareholders JSR Limited and Best Idea International Limited to organize the inquiry transfer [1] - The review process included verifying the registration certificates and compliance with relevant regulations for both JSR and Best Idea [2][4] Group 2 - JSR Limited was established on March 11, 2015, in the British Virgin Islands, and its main business is equity investment [2][3] - JSR has not violated any regulations regarding share reduction and is not a controlling shareholder of Mengke Pharmaceutical [3] - Best Idea International Limited was established on July 22, 2010, in Hong Kong, and its main business is also equity investment [4] - Best Idea has similarly complied with share reduction regulations and is not a controlling shareholder of Mengke Pharmaceutical [4][5] Group 3 - CICC concluded that both JSR and Best Idea meet the necessary qualifications for participating in the share inquiry transfer, with no violations of relevant regulations identified [5]